
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : TaiGen Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
TaiGen Enters Exclusive License Agreement with YSP
Details : Under the agreement, Y.S.P. will develop and commercialize TaiGen's new small molecule drug, TG-1000, a virus replication inhibitor, for infections, in Malaysia and Singapore.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : TaiGen Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
